Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period

著者: Andrea M. Haqq, Wendy K. Chung, Hélène Dollfus, Robert Haws, Gabriel Ángel Martos‐Moreno, Christine Poitou, Jack A. Yanovski, Robert S. Mittleman, Guojun Yuan, Elizabeth Forsythe, Karine Clément, Jesús Argente - The Lancet 2022 被引用: 182